The combination of immunoPET—where an antibody (Ab) is labeled with an isotope for PET imaging—and radioimmunotherapy (RIT), using the same antibody with a therapeutic isotope, offers significant advantages in cancer management. ImmunoPET allows non-invasive imaging of antigen expression, which aids in patient selection for subsequent radioimmunotherapy. It also facilitates the assessment of tumor response to therapy, allowing for treatment adjustments if necessary. In addition, immunoPET provides critical pharmacokinetic data, including antibody biodistribution and clearance rates, which are essential for dosimetry calculations and treatment protocol optimization. There are still challenges to overcome. Identifying appropriate target antigens that are selectively expressed on cancer cells while minimally expressed on normal tissues remains a major hurdle to reduce off-target toxicity. In addition, it is critical to optimize the pharmacokinetics of radiolabeled antibodies to maximize tumor uptake and minimize normal tissue uptake, particularly in vital organs such as the liver and kidney. This approach offers the potential for targeted and personalized cancer therapy with reduced systemic toxicity by exploiting the specificity of monoclonal antibodies and the cytotoxic effects of radiation. However, further research is needed to address remaining challenges and to optimize these technologies for clinical use.
免疫PET（即将抗体与同位素标记用于PET成像）与放射免疫疗法（使用相同抗体携带治疗性同位素）的结合，在癌症管理中展现出显著优势。免疫PET能够无创地显示抗原表达情况，有助于筛选适合接受后续放射免疫治疗的患者。同时，该方法可评估肿瘤对治疗的反应，便于必要时调整治疗方案。此外，免疫PET还能提供关键的药代动力学数据，包括抗体在体内的分布和清除率，这些数据对于剂量计算和治疗方案优化至关重要。 目前仍存在若干挑战需要克服。寻找在癌细胞上选择性表达、在正常组织中表达量最低的合适靶抗原，仍是降低脱靶毒性的主要难题。此外，优化放射性标记抗体的药代动力学特性也至关重要，这能最大化肿瘤摄取并减少正常组织（尤其是肝、肾等重要器官）的摄取。该方法通过利用单克隆抗体的特异性和辐射的细胞毒性作用，为实现靶向性、个性化癌症治疗并降低全身毒性提供了可能。然而，仍需进一步研究以解决现存挑战，并优化这些技术的临床应用。
肿瘤(癌症)患者之家